.Pharmacolibrary.Drugs.ATC.C.C01CA07

Information

Dobutamine is a synthetic catecholamine and direct-acting inotropic agent primarily used in the short-term treatment of cardiac decompensation due to depressed contractility resulting from organic heart disease or cardiac surgical procedures. It acts mainly through stimulation of beta-1 adrenergic receptors. Dobutamine is approved for use in acute heart failure and is administered intravenously in clinical settings.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers receiving short-term intravenous infusion.

References

1. Banner, W, et al., & Dean, JM (1991). Nonlinear dobutamine pharmacokinetics in a pediatric population. Critical care medicine 19(7) 871–873. DOI:10.1097/00003246-199107000-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2055074

2. Šíma, M, et al., & Slanař, O (2015). Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. Physiological research 64(Suppl 4) S513–S519. DOI:10.33549/physiolres.933213 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26681081

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)